Differential risk of adverse drug reactions with baricitinib across age groups: integrating real-world pharmacovigilance and genetic causal inference. [PDF]
Ther Adv Drug SafZeng H +8 more
europepmc +1 more source
Severe Hepatic Adverse Event Induced by Anti-HER2 Therapy in Breast Cancer: A Case of Successful Immunotherapy With Baricitinib. [PDF]
ACR Open RheumatolLi Y, Wang Y, Shao M, He J.
europepmc +1 more source
Revisiting Janus kinases as molecular drug targets for rheumatic diseases. [PDF]
Front Med (Lausanne)Kwon S.
europepmc +1 more source
Towards New Strategies: Case Report and Review of the Literature-Effective Use of JAK Inhibitor Baricitinib in a 4-Year-Old Boy with Anti-MDA5 Antibody-Positive Juvenile Dermatomyositis. [PDF]
J Clin MedBuzoianu O +3 more
europepmc +1 more source
Oral JΑΚ Inhibitors in Vitiligo Treatment. [PDF]
Dermatol Ther (Heidelb)Panagopoulou A +8 more
europepmc +1 more source
Baricitinib triggering a central nervous system inflammatory-demyelinating disease: A case report. [PDF]
Mult Scler J Exp Transl ClinKhalili R +3 more
europepmc +1 more source
Potential benefits of JAK inhibitor therapy in Blau syndrome: a case report. [PDF]
Front ImmunolWang Y, Yu XJ, Zhang Z.
europepmc +1 more source
JAK-Inhibitors Beyond the Label: Emerging Applications in Dermatology. [PDF]
Medicina (Kaunas)Foggi G +7 more
europepmc +1 more source
Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis. [PDF]
CureusBurashed KK, AlAbbasi FA.
europepmc +1 more source
Evidence Synthesis Gone Awry: The Perils of Aggregating Ineffective or Unsafe Doses in Alopecia Areata Reviews. [PDF]
CureusBabul A +4 more
europepmc +1 more source